CRISPR Therapeutics (CRSP) Competitors $47.26 +0.29 (+0.62%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CRSP vs. MNTA, NVAX, ALLO, SGMO, FATE, MRNA, NBIX, PCVX, TECH, and EXELShould you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Momenta Pharmaceuticals (MNTA), Novavax (NVAX), Allogene Therapeutics (ALLO), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE), Moderna (MRNA), Neurocrine Biosciences (NBIX), Vaxcyte (PCVX), Bio-Techne (TECH), and Exelixis (EXEL). These companies are all part of the "medical" sector. CRISPR Therapeutics vs. Momenta Pharmaceuticals Novavax Allogene Therapeutics Sangamo Therapeutics Fate Therapeutics Moderna Neurocrine Biosciences Vaxcyte Bio-Techne Exelixis Momenta Pharmaceuticals (NASDAQ:MNTA) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation. Does the media refer more to MNTA or CRSP? In the previous week, CRISPR Therapeutics had 12 more articles in the media than Momenta Pharmaceuticals. MarketBeat recorded 12 mentions for CRISPR Therapeutics and 0 mentions for Momenta Pharmaceuticals. CRISPR Therapeutics' average media sentiment score of 0.64 beat Momenta Pharmaceuticals' score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Momenta Pharmaceuticals Neutral CRISPR Therapeutics Positive Which has better earnings and valuation, MNTA or CRSP? CRISPR Therapeutics has higher revenue and earnings than Momenta Pharmaceuticals. Momenta Pharmaceuticals is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMomenta Pharmaceuticals$23.87M261.69-$290.05M-$3.03-17.32CRISPR Therapeutics$371.21M10.87-$153.61M-$2.83-16.70 Do analysts prefer MNTA or CRSP? CRISPR Therapeutics has a consensus price target of $74.94, suggesting a potential upside of 58.56%. Given CRISPR Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CRISPR Therapeutics is more favorable than Momenta Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Momenta Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00CRISPR Therapeutics 2 Sell rating(s) 8 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.37 Which has more risk and volatility, MNTA or CRSP? Momenta Pharmaceuticals has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Does the MarketBeat Community prefer MNTA or CRSP? Momenta Pharmaceuticals received 100 more outperform votes than CRISPR Therapeutics when rated by MarketBeat users. Likewise, 66.59% of users gave Momenta Pharmaceuticals an outperform vote while only 64.82% of users gave CRISPR Therapeutics an outperform vote. CompanyUnderperformOutperformMomenta PharmaceuticalsOutperform Votes56866.59% Underperform Votes28533.41% CRISPR TherapeuticsOutperform Votes46864.82% Underperform Votes25435.18% Is MNTA or CRSP more profitable? CRISPR Therapeutics has a net margin of -118.13% compared to Momenta Pharmaceuticals' net margin of -757.61%. CRISPR Therapeutics' return on equity of -12.15% beat Momenta Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Momenta Pharmaceuticals-757.61% -61.44% -45.28% CRISPR Therapeutics -118.13%-12.15%-10.35% Do institutionals and insiders hold more shares of MNTA or CRSP? 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 3.4% of Momenta Pharmaceuticals shares are owned by company insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryCRISPR Therapeutics beats Momenta Pharmaceuticals on 14 of the 18 factors compared between the two stocks. Ad Angel PublishingTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRSP vs. The Competition Export to ExcelMetricCRISPR TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.01B$2.93B$5.07B$8.89BDividend YieldN/A1.91%4.99%4.07%P/E Ratio-16.7015.0083.5712.93Price / Sales10.87280.711,220.3088.33Price / CashN/A168.0739.4636.25Price / Book2.084.696.936.25Net Income-$153.61M-$41.63M$119.12M$225.93M7 Day Performance0.88%-4.73%-1.83%-1.32%1 Month Performance-2.58%-6.53%-3.64%0.60%1 Year Performance-30.06%25.63%31.64%26.23% CRISPR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRSPCRISPR Therapeutics1.771 of 5 stars$47.26+0.6%$74.94+58.6%-34.5%$4.01B$371.21M-16.70473MNTAMomenta PharmaceuticalsN/A$52.48flatN/AN/A$6.25B$23.87M-17.32131NVAXNovavax3.6715 of 5 stars$8.06+0.8%$17.83+121.3%+41.4%$1.28B$983.71M0.001,543Analyst RevisionALLOAllogene Therapeutics2.7876 of 5 stars$2.05-3.3%$9.73+374.8%-31.4%$444.51M$90,000.000.00232Short Interest ↓SGMOSangamo Therapeutics2.1859 of 5 stars$1.95-0.5%$7.00+259.0%+369.9%$408.95M$176.23M0.00480Analyst RevisionGap UpFATEFate Therapeutics3.9121 of 5 stars$2.22+1.8%$6.75+204.1%-14.6%$248.29M$63.53M0.00550Analyst UpgradeMRNAModerna4.6286 of 5 stars$36.94-0.9%$84.00+127.4%-53.2%$14.35B$6.85B0.005,600Analyst UpgradeAnalyst RevisionNBIXNeurocrine Biosciences4.9503 of 5 stars$123.29+3.5%$163.91+32.9%+12.7%$12.06B$1.89B33.051,400Positive NewsPCVXVaxcyte3.2938 of 5 stars$85.96-1.3%$147.50+71.6%+67.2%$10.85BN/A0.00160TECHBio-Techne4.8558 of 5 stars$68.72+3.5%$81.78+19.0%+8.1%$10.55B$1.16B73.113,100EXELExelixis4.7763 of 5 stars$34.65+0.7%$31.44-9.3%+65.6%$9.83B$1.83B22.211,310Insider Trade Related Companies and Tools Related Companies Momenta Pharmaceuticals Alternatives Novavax Alternatives Allogene Therapeutics Alternatives Sangamo Therapeutics Alternatives Fate Therapeutics Alternatives Moderna Alternatives Neurocrine Biosciences Alternatives Vaxcyte Alternatives Bio-Techne Alternatives Exelixis Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRSP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRSP Stock Alerts